| scholarly article | Q13442814 |
| P2093 | author name string | Sandra Kurtin | |
| Lindsey Lyle | |||
| P2860 | cites work | The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 |
| Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management | Q26851894 | ||
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
| Efficacy and safety of low-dose aspirin in polycythemia vera | Q28166691 | ||
| Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study | Q28211348 | ||
| European consensus on grading bone marrow fibrosis and assessment of cellularity | Q33221061 | ||
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | Q33420037 | ||
| Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 | ||
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study | Q34037065 | ||
| Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. | Q34171747 | ||
| Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey | Q35938283 | ||
| Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study | Q36157668 | ||
| Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable | Q36266377 | ||
| 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q36429024 | ||
| Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs | Q36915139 | ||
| Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera | Q36938773 | ||
| ??? | Q28211186 | ||
| Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Q36946576 | ||
| Clinical applications of therapeutic phlebotomy | Q37118972 | ||
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 | ||
| Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. | Q37412790 | ||
| Therapy of pruritus | Q37738911 | ||
| Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond | Q37833893 | ||
| A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms | Q37955231 | ||
| An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms | Q38179853 | ||
| How to Treat Essential Thrombocythemia and Polycythemia Vera | Q38831700 | ||
| Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients | Q39810667 | ||
| Vascular and neoplastic risk in a large cohort of patients with polycythemia vera | Q40445951 | ||
| Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea | Q40560173 | ||
| Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy | Q41095829 | ||
| From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera | Q41345864 | ||
| A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process | Q43237567 | ||
| Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. | Q43863776 | ||
| Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. | Q44174767 | ||
| Cardiovascular events and intensity of treatment in polycythemia vera | Q44793541 | ||
| Masked polycythemia vera (mPV): results of an international study | Q46731979 | ||
| How I treat polycythemia vera. | Q48263925 | ||
| The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients | Q48680927 | ||
| Polycythemia vera masked due to severe iron deficiency anemia | Q50229131 | ||
| Long-acting interferon for myeloproliferative neoplasms - an update. | Q50489851 | ||
| How I treat polycythemia vera. | Q50510659 | ||
| A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. | Q53312448 | ||
| White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. | Q53410243 | ||
| Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. | Q53544139 | ||
| Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera | Q61146044 | ||
| In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology | Q61627770 | ||
| The Reticulin Content of Bone Marrow in Acute Leukaemia in Adults | Q66971031 | ||
| A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera | Q72031918 | ||
| Iron out the details of therapeutic phlebotomy | Q75394661 | ||
| Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha | Q79805117 | ||
| Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment | Q80866784 | ||
| Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia | Q80996436 | ||
| The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers | Q84165137 | ||
| Epidemiology of myeloproliferative neoplasms in the United States | Q86953148 | ||
| P433 | issue | 1 | |
| P921 | main subject | polycythemia vera | Q948318 |
| P304 | page(s) | 56-66 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Journal of the advanced practitioner in oncology | Q26841994 |
| P1476 | title | The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera | |
| P478 | volume | 9 |
Search more.